Skip to Main Content

For further information, see CMDT Part 32-06: Common Viral Respiratory Infections

Key Features

  • Bronchiolitis, proliferation and necrosis of bronchiolar epithelium develop, producing obstruction from sloughed epithelium and increased mucus secretion

  • Apnea, low-grade fever, tachypnea, and wheezes

  • Hyperinflated lungs, decreased gas exchange, and increased work of breathing

  • Prematurity is a major risk factor for severe disease

Clinical Findings

  • Annual epidemics occur in winter and spring

  • Average incubation period is 5 days

  • Inoculation may occur through the nose or the eyes

  • In children

    • Most common cause of acute lower respiratory infection

    • Common cause of acute and recurrent otitis media

  • In adults

    • Causes upper and lower respiratory tract infection with increasingly recognized severity in

      • Persons with comorbid conditions

      • Elderly persons

      • Persons with severe combined immunodeficiency

      • Persons who have undergone lung or bone marrow transplantation

    • Recurrent infections occur throughout life

  • In immunocompromised patients, such as bone marrow transplant recipients, serious pneumonia can occur

Diagnosis

  • Polymerase chain reaction (PCR) is increasingly used

  • Rapid diagnosis possible by viral antigen identification in nasal washings using an ELISA or immunofluorescent assay

  • Multiplex assays in conjunction with influenza A and B tests are available commercially

  • RSV viral load assay values at day 3 of infection correlate with requirement of intensive care and respiratory failure

Treatment

  • Hydration, humidification of inspired air, antibiotic therapy, and ventilatory support as needed

  • In non–high-risk populations, ribavirin, bronchodilators, and corticosteroids are widely used, but evidence for their effectiveness is lacking

    • Ribavirin contraindicated in pregnancy

  • Palivizumab

    • Prophylactic monoclonal antibody

    • Effective in high-risk infants (congenital heart and lung diseases, Down syndrome)

    • Significantly lowers incidence of recurrent wheezing

    • Not proven effective among adults with RSV

  • Azithromycin therapy has been shown to reduce the probability of recurrent wheezing during the subsequent year by approximately 50%

Pop-up div Successfully Displayed

This div only appears when the trigger link is hovered over. Otherwise it is hidden from view.